Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,477 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Insulin Dependent Diabetes Mellitus 1 Clear all
Completed Phase 1 Interventional

Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes

NCT04625595
View directory record Official record
Conditions
Type1 Diabetes
Interventions
350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Drug
Lead sponsor
Immunomolecular Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Chula Vista, California • Aurora, Colorado • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 20, 2026, 11:43 AM EDT
Not yet recruiting Not applicable Interventional

Insul-In This Together: Leveraging Family Support and Diabetes Technology for Adolescents Living With Type 1 Diabetes

NCT07856836
View directory record Official record
Conditions
Diabetes Type 1
Interventions
Insul-In This Together
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2032
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Incorporating Mind-body Skills With Diabetes Education in Adolescents With Type 1 Diabetes

NCT05577169
View directory record Official record
Conditions
Type 1 Diabetes, Adolescent Behavior
Interventions
Mind-body skills, Diabetes education
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
15 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting

NCT01638299
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hypo-Hyper Minimizer (HHM) System
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Not applicable Interventional Results available

Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents

NCT02714972
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia, Hyperglycemia, Artificial Pancreas
Interventions
Hyperglycemia Minimization Algorithm
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Years to 14 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 11:43 AM EDT
Active, not recruiting Phase 2 Interventional

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes

NCT05180591
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes
Interventions
Bacillus Calmette-Guérin, Saline Injection
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Pet Ownership and Glucose Control in Type 1 Diabetes

NCT01733524
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pet Fish, Picture of a fish
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

NCT01654380
View directory record Official record
Conditions
Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions
LY2605541, Insulin glargine
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Not applicable Interventional Results available

PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm

NCT03251079
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous glucose monitoring system
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Escondido, California • Walnut Creek, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes

NCT01586065
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Not applicable Interventional Results available

Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes

NCT02734667
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM at diagnosis of T1D
Device
Lead sponsor
Korey Hood
Other
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 20, 2026, 11:43 AM EDT
Not listed Not applicable Interventional

Improving Diabetes Equity and Advancing Care Study

NCT06040463
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support
Behavioral
Lead sponsor
Sinai Health System
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3

NCT00742521
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
glucose clamp
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 20, 2026, 11:43 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Circulating Biomarkers in the Development of Type 1 Diabetes

NCT05505669
View directory record Official record
Conditions
Diabetes
Interventions
One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

NCT00313183
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Aurora, Colorado • Kansas City, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop MPC vs Control IQ

NCT05799781
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MPC closed-loop system, t:slim X2 pump with Dexcom G6 CGM and Control IQ
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

NCT04740307
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Duarte, California • Baltimore, Maryland • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 20, 2026, 11:43 AM EDT
Terminated Phase 1 Interventional

Islet Cell Transplants for Diabetes

NCT00303134
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplantation
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 20, 2026, 11:43 AM EDT
Not listed Phase 2 Interventional

Ingested Interferon Alpha: Prolongation or Permanence of the "Honeymoon" Phase in Newly Diagnosed Type 1 Diabetes Mellitus

NCT00005665
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
interferon alpha
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
3 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Phase 4 Interventional Results available

Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

NCT00442767
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin, Pramlintide + Insulin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 20, 2026, 11:43 AM EDT
Recruiting Not applicable Interventional

Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes

NCT06236607
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Complications
Interventions
Device specific training, Study clinician/educator visit
Device · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Not applicable Interventional Results available

Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use

NCT02137512
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed-Loop Control System, Sensor-Augmented Pump (SAP)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 69 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Santa Barbara, California • Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 20, 2026, 11:43 AM EDT
Recruiting Phase 2 Interventional

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
High Dose SAB-142, Low Dose SAB-142, Placebo
Drug · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
5 Years to 40 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
San Francisco, California • San Jose, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 11:43 AM EDT
Completed Not applicable Interventional Results available

Development of Algorithms for a Hypoglycemic Prevention Alarm: Closed Loop Study

NCT00884611
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Predictive Low Glucose Suspend Algorithm ON, Predictive Low Glucose Suspend Algorithm OFF
Device
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 46 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 20, 2026, 11:43 AM EDT